Tibolone and breast cancer

Postgraduate Medical Journal

Volumn 82, Issue 972, 2006, Pages 658-662

  Erel, C Tamer ^a   Senturk, Levent M ^a   Kaleli, Semih ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; MEDROXYPROGESTERONE ACETATE; NOMEGESTROL; NORETHISTERONE ACETATE; PROGESTERONE; PROGESTERONE RECEPTOR; RALOXIFENE; TAMOXIFEN; TIBOLONE;

BREAST CANCER; BREAST CELL; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ESTROGEN ACTIVITY; HISTOPATHOLOGY; HORMONE ACTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; IN VITRO STUDY; NONHUMAN; POSTMENOPAUSE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; MACACA FASCICULARIS; NORPREGNENES; RATS;

EID: 33751226923     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2005.037184     Document Type: Review

References (46)

1. Palocios S. Tibolone. What does tissue specific activity mean? Maturitas 2001;37:159-05.
2. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. Steroid Biochem Mol Biol 2001;76:231-8.
3. Tang BLK, Markiewicz HJ, Gurpide E. Human endometrial 3α-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/ progestagenic activity ratios of a steroidal drug (OrgOD14). J Steroid Biochem Mol Biol 1993;45:345-51.
4. Markiewicz L, Gurpide E. Estrogenic and progestagenic activities coexisting in steroidal drugs: quantitative evaluation by in vitro bioassays with human cells. J Steroid Biochem Mol Biol 1994;48:89-94.
5. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trial. J Clin Endocrinol Metab 2002;87:16-23.
6. Pasqualini JR, Chetrite GS. Recent insight on lhe control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 2005;93:221-36.
7. Cherite G, Kloosterboer HJ, Pasqualini JR. Effect of tibolone (Org OD14) and ils metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 1997;17:135-40.
8. Pasqualini JR, Kloosterboer HJ. Estrone sulfatase and 17β-hydroxysteroid dehydrogenase activities in human breast cancer. Inhibitory effect by tibolone and its metabolites. Acta Obstet Gynaecol Scand 1997;76(Suppl 167):35.
9. Chetrite GS, Klcosterboer HJ, Philippe JC, et al. Effect of Org OD14 (Livial®) and its metabolites on human estrogen sulphotransferase activity in the hormone-dependent MCF-7 and T- 47D, and the hormone independent MDA-MB-231, breast cancer cells lines. Anticancer Res 1999;19:269-76.
10. Gompel A, Chaouat M, Jacob D, et al. In vitro studies of tibolone in breast cells. Fertil Steril 2002;78:351-9.
11. Mirkin S, Wong BC, Archer DF. Effect of 17β-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril 2005;84:485-91.
12. Gooyer de ME, Oppers-Tiemissen HM, Leysen D, et al. Tibolone is not converted by human aromatase to 7α-methyl-17α-ethynylestradiol (7α-MEE): analyses with sensitive bioassays for estrogens and androgens and with LC-MS/MS. Steroids 2003;68:235-43.
13. van de Ven J, Donker G, Sprang M, et al. Effect of tibolone (Org OD14) and its metabolites on aromatase and estrone sulfatase activity in human breast adipose stromal cells and in MCF-7 and T47D breast cancer cells. J Steroid Biochem Mol Biol 2002;81:237-47.
14. Lippert C, Seeger H, Wallwiener D, et al. Tibolone versus 17beta-estradiol/ norethislerone: effects on the proliferation of human breast cancer cells, fur 1 Gynaecol Oncol 2002;23:127-30.
15. Kloosterboer HJ, Schoonen WG, Deckers GH, et al. Effects of progestrogens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol 1994;49:311-18.
16. Caline J, Cono A, Medina M, et al. Hormonal environment in the induction of breast cancer in castrated rats using dimethylbenzanthracene: influence of the presence or absence of ovarian activity and of treatment with estradiol, tibolone, and raloxifene. Menopause 2005;12:601-8.
17. Cline JM, Register TC, Clarkson TB. Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause 2002;9:422-9.
18. Conner P, Register PC, Skoog L, et al. Expression of p53 and markers for apoptosis in breast tissue during long-term hormone therapy in cynomolgus monkeys. Am J Obstet Gynecol 2005;193:58-63.
19. Litherland JC, Evans AJ, Wilson AR. The effect of hormone replacement therapy on recall rate in the National Health Service Breast Screening Programme. Clin Radiol 1997;52:276-9.
20. Limerland JC, Stallard S, Hole D, et al. The effect of hormone replacement therapy on the sensitivity of screening mammograms. Clin Radiol 1999;54:285-8.
21. Boyd NF, Jensen HM, Cooke G, et al. Mammographic densities and the prevalence and incidence of histological types of benign breast disease. Eur J Cancer Prev 2000;9:15-24.
22. Valdivia I, Campodónico I, Tapia A, et al. Effect of tibolone and continuous combined hormone replacement therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004;81:617-23.
23. Conner P, Christow A, Kersemaekers W. A comparative study on breast cell proliferation during HRT effects of tibolone and continuous combined estrogen progestogen treatment. Climacteric 2004;7:50-8.
24. Erel CT, Seyisoǧlu H, Şentürk ML, et al. Mammographic changes in women on hormonal replacement therapy. Maturitas 1996;25:51-7.
25. Greendate GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogenprogestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-9.
26. Lundstrom E, Wilczek B, vonPalffy Z, et al. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999;181:348-52.
27. Sendag F, Cosan Terek M, Ozsener S, et al. Mammographic density changes during different postmenopausal hormone replacement therapies, Fertil Steril 2001;76:445-50.
28. Erel CT, Esen G, Seyisoglu H, et al. Mammographic density increase in women receiving different hormone replacement regimens. Maturitas 2001;40:151-7.
29. Lundstrom E, Wilczek B, von Palffy Z, et al. Mammographic breast density during hormone replacement therapy: efects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric 2001;4:42-8.
30. Colacurci N, Fornaro F, DeFranciscis P, et al. Effects of a short-term suspension of hormone replacement therapy on mammographic density. Fertil Steril 2001;76:451-5.
31. Erel CT, Eiter K, Akman C, et al. Mammographic changes in women receiving tibolone therapy. Fertil Steril 1998;69:870-5.
32. Colacurci N, Mele D, De Franciscis P, et al. Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol 1998;80:235-8.
33. Ozdemir A, Konus O, Nas T, et al. Mammographic and ultrasonographic study of changes in the breast related to HRT. Int J Gynaecol Obstet 1999;67:23-32.
34. Colocurci N, Fornaro F, De Franciscis P, et al. Effects of different types of hormone replacement therapy on mammographic density. Maturitas 2001;40:159-64.
35. Egarter C, Eppel W, Vogel S, et al. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breasts. Maturitas 2001;40:165-71.
36. Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717-22.
37. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, et al. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002;9:110-16.
38. Bulbul NH, Ozden S, Dayicioglu V. Effects of hormone replacement therapy on mammographic findings. Arch Gynecol Obstet 2003;268:5-8.
39. Bruce D, Robinson J, McWilliams S, et al. Long-term effects of tibolone on mammographic density. Fertil Steril 2004;82:1343-7.
40. Marcnesoni D, Driul L, lanni A, et al. Postmenopausal hormone therapy and mammographic breast density. Maturitas 2006;53:59-64.
41. Yenen MC, Dede M, Goktolga U, et al. Hormone replacement therapy in postmenopausal women with benign fibrocystic mastopathy. Climacteric 2003;6:146-50.
42. Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
43. Wierik EJ, Hendricks PT, Boerstoel-Streefland M. Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus study. Climacteric 2004;7:197-209.
44. Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast cancer following different regimens of normone replacement therapy frequently used in Europe. Int J Cancer 2004;109:721-7.
45. Kroiss R, Fentiman IS, Helmond FA, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placeoo-controlled trial. BJOG 2005;112:228-33.
46. Writing Group for the WHI Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-33.